Latigo Biotherapeutics Posts $27.59 Q2 Loss Per Share
LTGO sits 31% above its 52-week low of $17.22.
Summary
Latigo Biotherapeutics reported a Q2 loss of $27.59 per share, a substantial figure for a company that just completed its IPO on August 10 at $18.00 per share. The loss is likely driven by heavy R&D spending typical of a clinical-stage biotech, but the magnitude relative to the IPO price is notable. This is the first earnings disclosure since the IPO, and it provides the market with a concrete look at the company's burn rate. Investors will compare this loss to the $345.6 million raised in the IPO to gauge runway. The stock closed at $22.48, suggesting the market may have already priced in significant losses, but this official number could still trigger repositioning. The company's total Q2 loss was $25.8 million.
At the time of this announcement, LTGO was trading at $22.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $17.22 to $25.93. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.